Intellicell Biosciences Inc (fka SVFC)

[BigBadWolf]

120K for nine months as per filing...just to be factual & should I go back & divide that by the 9 months of expenses as $$All of the $$Investing $$Public has seen what $$Hope $$Awesome $$Hype & $$SVFC $$Failed $$Dreams has done to $$shareholder $$value ever Since .078 in 7-12-2013 to 0001 again today 11/20/14 to $$coincide with $$declining $$shareholder $$value $$Billions of $$shares $$trading @ 000485 w/ $$NO $$Bid so .078 down to 0000485

my calculations are based on FACTS those provide by you are just more $$Hope $$Hype $$Fact

and mine show why the shareholder deficit & share structure continue to increase, again $$FACT & I deal in facts that have been available to ALL all along


now those revenues of 55,000 (3 months) divided by expenses of 355,570 (3 months) = 15.5% Revenues covered 15.5% of expenses for the same period excluding the multiple Convertible Debenture Agreements, any monthly fees owed, & interest accrued & their cost to shareholder value

And nothing has changed as it relates to $$YA $$Global's $$CDA $$Collateral $$Options $$Control http://investorshub.advfn.com/boards/read_msg.aspx?message_id=108353947

TOTAL STOCKHOLDERS' DEFICIT (14,426,668) (12,281,351)

an increase in $$Stockholders' $$Deficit of $2,145,317

For The Three Months Ended For The Nine Months Ended
September 30 2014 September 30 2013 September 30 2014 September 30 2013
REVENUES:
Revenues - related party $55,000 $120,000

now those revenues of 55,000 (3 months) divided by 355,570 (3 months) = 15.5% Revenues covered 15.5% of expenses for the same period

Operating expenses

Research and development expenses were $117,137 and $387,637 for three months and nine months ended September 30, 2014 as compared to $14,587 and $516,390 for the three months and nine months ended September 30, 2013, respectively. The principal component of research and development costs consists of services as the attending physician in patient cases, for lab technicians, and for nursing staff employed by Dr. Victor’s medical practice included as part of the ongoing research of our technologies and processes.

http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=10316093 pg. 46

Salary Expense

General and administrative is comprised of salary expenses of $133,706 and $470,319 for the three months and nine months ended September 30, 2014 as compared to $113,750 and $599,068 for the three months and nine months ended September 30, 2013, respectively. Included in the salary expense for each of the three months and nine months ended September 30, 2014 was $68,750 and $206,250 paid to a significant shareholder as a result of this individual serving in the capacity of our Chief Executive Officer, as compared to $68,750 and $206,250 for the three months and nine months ended September 30, 2013 In addition, the Company incurred administrative salary expense of $45,000 and $135,000 for the three months and nine months ended September 30, 2014 and June 30, 2013, respectively, to the spouse of the Company’s Chief Executive Officer and majority shareholder.

Rent and office administrative expenses

Included in general and administrative expenses are $104,727 and $320,076 of rent and related occupancy expenses for the three months and nine months ended September 30, 2014, as compared to $103,800 and $311,400 for the three months and nine months ended September 30 2013, respectively. Rent is for the office space and Tissue Processing Lab located at 460 Park Avenue, NY, NY aka Regen Medical Vic's private practice